Commentary
Video
Author(s):
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML
Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
Five Under 5: Top Oncology Videos for the Week of 1/26
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
Real-World Analysis Shows Superior Efficacy With Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma
MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia
Envafolimab Plus Suvemcitug and FOLFIRI Shows Early Efficacy, Tolerability in Second-Line CRC
Emerging Data Continue to Shape the Role of Blinatumomab in Acute Lymphoblastic Leukemia
NX-5948 Demonstrates Preliminary Efficacy in High-Risk CLL